Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review

Advances in Pediatrics

Volumn 57, Issue 1, 2010, Pages 85-140

  Lindbäck, Sarah M ^a   Gabbert, Charles ^a,b   Johnson, Benjamin L ^c   Smorodinsky, Emmanuil ^b,c   Sirlin, Claude B ^c   Garcia, Natalie ^b   Pardee, Perrie E ^a   Kistler, Kristin D ^a   Schwimmer, Jeffrey B ^a,c,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE;

ADOLESCENT; AGE DISTRIBUTION; BLOOD; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER FLOWMETRY; EARLY DIAGNOSIS; ETHNIC GROUP; FATTY LIVER; FEMALE; HEPATOMEGALY; HOSPITALIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; METABOLISM; METHODOLOGY; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; QUALITY OF LIFE; REVIEW; SEX RATIO; STATISTICS; UNITED STATES;

ADOLESCENT; AGE DISTRIBUTION; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CALIFORNIA; CHILD; CHILD, PRESCHOOL; CYTOKINES; EARLY DIAGNOSIS; ETHNIC GROUPS; FATTY LIVER; FEMALE; HEPATOMEGALY; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER;

EID: 78149381906     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2010.08.006     Document Type: Review

References (230)

1. Brunt E.M. Pathology of fatty liver disease. Mod Pathol 2007, 20(Suppl 1):S40-S48.
2. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
3. Brunt E.M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16.
4. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
5. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
6. Mendler M.H., Kanel G., Govindarajan S. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int 2005, 25:294-304.
7. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
8. Brunt E.M. Nonalcoholic steatohepatitis. Semin Liver Dis 2004, 24:3-20.
9. Chalasani N., Wilson L., Kleiner D.E., et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008, 48:829-834.
10. Schaff Z., Lapis K. Fine structure of hepatocytes during the etiology of several common pathologies. J Electron Microsc Tech 1990, 14:179-207.
11. Lackner C., Gogg-Kamerer M., Zatloukal K., et al. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008, 48:821-828.
12. Schwimmer J.B., Behling C., Newbury R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005, 42:641-649.
13. Nobili V., Marcellini M., Devito R., et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006, 44:458-465.
14. Carter-Kent C., Yerian L.M., Brunt E.M., et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009, 50:1113-1120.
15. Ko J.S., Yoon J.M., Yang H.R., et al. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 2009, 54:2225-2230.
16. Xanthakos S., Miles L., Bucuvalas J., et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006, 4:226-232.
17. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009, 49:809-820.
18. Adani G.L., Baccarani U., Sainz-Barriga M., et al. The role of hepatic biopsy to detect macrovacuolar steatosis during liver procurement. Transplant Proc 2006, 38:1404-1406.
19. Joy D., Thava V.R., Scott B.B. Diagnosis of fatty liver disease: is biopsy necessary?. Eur J Gastroenterol Hepatol 2003, 15:539-543.
20. Longo R., Pollesello P., Ricci C., et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995, 5:281-285.
21. Lupsor M., Badea R. Imaging diagnosis and quantification of hepatic steatosis: is it an accepted alternative to needle biopsy?. Rom J Gastroenterol 2005, 14:419-425.
22. Smith E.H. Complications of percutaneous abdominal fine-needle biopsy. Radiology 1991, 178:253-258. [review].
23. Schwimmer J.B., Deutsch R., Rauch J.B., et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003, 143:500-505.
24. Nobili V., Manco M., Ciampalini P., et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol 2006, 155:735-743.
25. Patton H.M., Lavine J.E., Van Natta M.L., et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1961-1971. e1962.
26. Nobili V., Alkhouri N., Alisi A., et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:575-579.
27. Poynard T., Ratziu V., Charlotte F., et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:34.
28. Miele L., Forgione A., La Torre G., et al. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res 2009, 154:194-201.
29. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
30. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
31. Wieckowska A., Zein N.N., Yerian L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
32. Feldstein A.E., Wieckowska A., Lopez A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
33. Mitry R.R., De Bruyne R., Quaglia A., et al. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers. Hepatology 2007, 46:2047-2048. author reply 2048.
34. Nobili V., Parkes J., Bottazzo G., et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009, 136:160-167.
35. Yajima Y., Ohta K., Narui T., et al. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983, 139:43-50.
36. Zwiebel W.J. Sonographic diagnosis of diffuse liver disease. Semin Ultrasound CT MR 1995, 16:8-15.
37. Karcaaltincaba M., Akhan O. Imaging of hepatic steatosis and fatty sparing. Eur J Radiol 2007, 61:33-43.
38. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
39. Pacifico L., Celestre M., Anania C., et al. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr 2007, 96:542-547.
40. Graif M., Yanuka M., Baraz M., et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol 2000, 35:319-324.
41. Joseph A.E., Saverymuttu S.H., al-Sam S., et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991, 43:26-31.
42. Mathiesen U.L., Franzen L.E., Aselius H., et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002, 34:516-522.
43. Saverymuttu S.H., Joseph A.E., Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986, 292:13-15.
44. Ali R., Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009, 41:265-278.
45. Celle G., Savarino V., Picciotto A., et al. Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. Dig Dis Sci 1988, 33:467-471.
46. Hepburn M.J., Vos J.A., Fillman E.P., et al. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol 2005, 5:14.
47. Needleman L., Kurtz A.B., Rifkin M.D., et al. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. AJR Am J Roentgenol 1986, 146:1011-1015.
48. Strauss S., Gavish E., Gottlieb P., et al. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007, 189:W320-W323.
49. Bydder G.M., Chapman R.W., Harry D., et al. Computed tomography attenuation values in fatty liver. J Comput Tomogr 1981, 5:33-35.
50. Speliotes E.K., Massaro J.M., Hoffmann U., et al. Liver fat is reproducibly measured using computed tomography in the Framingham Heart Study. J Gastroenterol Hepatol 2008, 23:894-899.
51. Limanond P., Raman S.S., Lassman C., et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004, 230:276-280.
52. Lee S.W., Park S.H., Kim K.W., et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology 2007, 244:479-485.
53. Schwimmer J.B. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin Liver Dis 2007, 27:312-318.
54. Hamer O.W., Aguirre D.A., Casola G., et al. Fatty liver: imaging patterns and pitfalls. Radiographics 2006, 26:1637-1653.
55. Siegelman E.S., Rosen M.A. Imaging of hepatic steatosis. Semin Liver Dis 2001, 21:71-80.
56. Mehta S.R., Thomas E.L., Bell J.D., et al. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008, 14:3476-3483.
57. Cassidy F.H., Yokoo T., Aganovic L., et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics 2009, 29:231-260.
58. Longo R., Ricci C., Masutti F., et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993, 28:297-302.
59. Thomsen C., Becker U., Winkler K., et al. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994, 12:487-495.
60. Kim H., Taksali S.E., Dufour S., et al. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL. Magn Reson Med 2008, 59:521-527.
61. Thomas E.L., Hamilton G., Patel N., et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005, 54:122-127.
62. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
63. Szczepaniak L.S., Nurenberg P., Leonard D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
64. Vuppalanchi R., Cummings O.W., Saxena R., et al. Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol 2007, 41:206-210.
65. Bugianesi E., Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
66. Carey D.G., Cowin G.J., Galloway G.J., et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002, 10:1008-1015.
67. Schwimmer J.B., Middleton M.S., Deutsch R., et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005, 21:871-879.
68. Hamilton G., Middleton M.S., Bydder M., et al. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging 2009, 30:145-152.
69. Taouli B., Ehman R.L., Reeder S.B. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol 2009, 193:14-27.
70. Dixon W.T. Simple proton spectroscopic imaging. Radiology 1984, 153:189-194.
71. Sirlin C.B. Noninvasive imaging biomarkers for steatosis assessment. Liver Transpl 2009, 15:1389-1391.
72. Mazhar S.M., Shiehmorteza M., Sirlin C.B. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009, 7:135-140.
73. Fishbein M., Castro F., Cheruku S., et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005, 39:619-625.
74. Kim S.H., Lee J.M., Han J.K., et al. Hepatic macrosteatosis: predicting appropriateness of liver donation by using MR imaging-correlation with histopathologic findings. Radiology 2006, 240:116-129.
75. Qayyum A., Goh J.S., Kakar S., et al. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques-initial experience. Radiology 2005, 237:507-511.
76. Borra R.J., Salo S., Dean K., et al. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. Radiology 2009, 250:130-136.
77. Fishbein M.H., Gardner K.G., Potter C.J., et al. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 1997, 15:287-293.
78. Hussain H.K., Chenevert T.L., Londy F.J., et al. Hepatic fat fraction: MR imaging for quantitative measurement and display-early experience. Radiology 2005, 237:1048-1055.
79. Bydder M., Yokoo T., Hamilton G., et al. Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging 2008, 26:347-359.
80. Liu C.Y., McKenzie C.A., Yu H., et al. Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise. Magn Reson Med 2007, 58:354-364.
81. Yokoo T., Bydder M., Hamilton G., et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009, 251:67-76.
82. Brix G., Heiland S., Bellemann M.E., et al. MR imaging of fat-containing tissues: valuation of two quantitative imaging techniques in comparison with localized proton spectroscopy. Magn Reson Imaging 1993, 11:977-991.
83. Reeder S.B., Robson P.M., Yu H., et al. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 2009, 29:1332-1339.
84. Yu H., Shimakawa A., McKenzie C.A., et al. Multiecho water-fat separation and simultaneous R2i estimation with multifrequency fat spectrum modeling. Magn Reson Med 2008, 60:1122-1134.
85. Hines C.D., Yu H., Shimakawa A., et al. T1 independent, T2i corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom. J Magn Reson Imaging 2009, 30:1215-1222.
86. Huwart L., Sempoux C., Vicaut E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008, 135:32-40.
87. Sandrin L., Fourquet B., Hasquenoph J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-1713.
88. Yeh W.C., Li P.C., Jeng Y.M., et al. Elastic modulus measurements of human liver and correlation with pathology. Ultrasound Med Biol 2002, 28:467-474.
89. Yoneda M., Yoneda M., Mawatari H., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008, 40:371-378.
90. Nobili V., Vizzutti F., Arena U., et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008, 48:442-448.
91. Fraquelli M., Rigamonti C., Casazza G., et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007, 56:968-973.
92. Coco B., Oliveri F., Maina A.M., et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007, 14:360-369.
93. Lebray P., Varnous S., Charlotte F., et al. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 2008, 48:2089.
94. Ganne-Carrie N., Ziol M., de Ledinghen V., et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006, 44:1511-1517.
95. Ito K., Mitchell D.G., Siegelman E.S. Cirrhosis: MR imaging features. Magn Reson Imaging Clin N Am 2002, 10:75-92. vi.
96. Martin D.R. Magnetic resonance imaging of diffuse liver diseases. Top Magn Reson Imaging 2002, 13:151-163.
97. Brancatelli G., Federle M.P., Ambrosini R., et al. Cirrhosis: CT and MR imaging evaluation. Eur J Radiol 2007, 61:57-69.
98. Aguirre D.A., Behling C.A., Alpert E., et al. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006, 239:425-437.
99. Hughes-Cassidy F., Chavez A.D., Schlang A., et al. Superparamagnetic iron oxides and low molecular weight gadolinium chelates are synergistic for direct visualization of advanced liver fibrosis. J Magn Reson Imaging 2007, 26:728-737.
100. Faria S.C., Ganesan K., Mwangi I., et al. MR imaging of liver fibrosis: current state of the art. Radiographics 2009, 29:1615-1635.
101. Semelka R.C., Chung J.J., Hussain S.M., et al. Chronic hepatitis: correlation of early patchy and late linear enhancement patterns on gadolinium-enhanced MR images with histopathology initial experience. J Magn Reson Imaging 2001, 13:385-391.
102. Ide M., Yamate J., Machida Y., et al. Emergence of different macrophage populations in hepatic fibrosis following thioacetamide-induced acute hepatocyte injury in rats. J Comp Pathol 2003, 128:41-51.
103. Lieber C.S. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004, 34:9-19.
104. Tanimoto A., Yuasa Y., Shinmoto H., et al. Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function. Radiology 2002, 222:661-666.
105. Hanna R.F., Kased N., Kwan S.W., et al. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol 2008, 190:47-57.
106. Bensamoun S.F., Wang L., Robert L., et al. Measurement of liver stiffness with two imaging techniques: magnetic resonance elastography and ultrasound elastometry. J Magn Reson Imaging 2008, 28:1287-1292.
107. Rouviere O., Yin M., Dresner M.A., et al. MR elastography of the liver: preliminary results. Radiology 2006, 240:440-448.
108. Yin M., Talwalkar J.A., Glaser K.J., et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007, 5:1207-1213. e1202.
109. Talwalkar J.A., Yin M., Fidler J.L., et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008, 47:332-342.
110. Pardee P.E., Lavine J.E., Schwimmer J.B. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg 2009, 18:144-151.
111. Kahn C.R., Flier J.S., Bar R.S., et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976, 294:739-745.
112. Moller D.E., Flier J.S. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991, 325:938-948.
113. Poretsky L., Piper B. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol 1994, 84:613-621.
114. Jeanrenaud B. Hyperinsulinemia in obesity syndromes: its metabolic consequences and possible etiology. Metabolism 1978, 27:1881-1892.
115. Barrows B.R., Parks E.J. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab 2006, 91:1446-1452.
116. Donnelly K.L., Smith C.I., Schwarzenberg S.J., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
117. Fabbrini E., deHaseth D., Deivanayagam S., et al. Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity (Silver Spring) 2009, 17:25-29.
118. Boden G., She P., Mozzoli M., et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005, 54:3458-3465.
119. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
120. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010, 11:430-445.
121. Li Z., Berk M., McIntyre T.M., et al. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008, 47:1495-1503.
122. Connolly M.K., Bedrosian A.S., Mallen-St Clair J., et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009, 119:3213-3225.
123. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells. Hepatology 2006, 44:1487-1501.
124. Wang J., Leclercq I., Brymora J.M., et al. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009, 137:713-723.
125. Louthan M.V., Barve S., McClain C.J., et al. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005, 147:835-838.
126. Burgert T.S., Taksali S.E., Dziura J., et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 2006, 91:4287-4294.
127. Asano T., Watanabe K., Kubota N., et al. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 2009, 24:1669-1676.
128. Fukushima J., Kamada Y., Matsumoto H., et al. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res 2009, 39:724-738.
129. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
130. Rigazio S., Lehto H.R., Tuunanen H., et al. The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans. Am J Physiol Endocrinol Metab 2008, 295:E413-E419.
131. Bruce K.D., Cagampang F.R., Argenton M., et al. Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology 2009, 50:1796-1808.
132. McCurdy C.E., Bishop J.M., Williams S.M., et al. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J Clin Invest 2009, 119:323-335.
133. Schwimmer J.B., Deutsch R., Kahen T., et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118:1388-1393.
134. Schwimmer J.B., Celedon M.A., Lavine J.E., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136:1585-1592.
135. Wagenknecht L.E., Scherzinger A.L., Stamm E.R., et al. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring) 2009, 17:1240-1246.
136. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
137. Kotronen A., Johansson L.E., Johansson L.M., et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52:1056-1060.
138. Sookoian S., Castano G.O., Burgueno A.L., et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009, 50:2111-2116.
139. Wilson P.A., Gardner S.D., Lambie N.M., et al. Characterization of the human patatin-like phospholipase family. J Lipid Res 2006, 47:1940-1949.
140. Kollerits B., Coassin S., Beckmann N.D., et al. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum Mol Genet 2009, 18:4669-4676.
141. Fraser A., Longnecker M.P., Lawlor D.A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007, 133:1814-1820.
142. Kawasaki T., Hashimoto N., Kikuchi T., et al. The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr 1997, 24:317-321.
143. Sagi R., Reif S., Neuman G., et al. Nonalcoholic fatty liver disease in overweight children and adolescents. Acta Paediatr 2007, 96:1209-1213.
144. Nadeau K.J., Ehlers L.B., Zeitler P.S., et al. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 2009, 10:5-13.
145. Schwimmer J.B., McGreal N., Deutsch R., et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005, 115:e561-e565.
146. Quirós-Tejeira R.E., Rivera C.A., Ziba T.T., et al. Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or =95th percentile. J Pediatr Gastroenterol Nutr 2007, 44:228-236.
147. Sartorio A., Del Col A., Agosti F., et al. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007, 61:877-883.
148. Louthan M.V., Theriot J.A., Zimmerman E., et al. Decreased prevalence of nonalcoholic fatty liver disease in black obese children. J Pediatr Gastroenterol Nutr 2005, 41:426-429.
149. Kistler K.D., Molleston J., Unalp A., et al. Symptoms and quality of life in obese children and adolescents with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009, 31:396-406.
150. Hh A.K., Henderson J., Vanhoesen K., et al. Nonalcoholic fatty liver disease in children: a single center experience. Clin Gastroenterol Hepatol 2008, 6:799-802.
151. Rhee H., Miles M.S., Halpern C.T., et al. Prevalence of recurrent physical symptoms in U.S. adolescents. Pediatr Nurs 2005, 31:314-319. 350.
152. Riley M.R., Bass N.M., Rosenthal P., et al. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr 2005, 147:839-842.
153. Barlow S.E. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007, 120(Suppl 4):S164-S192.
154. Schwimmer J.B., Dunn W., Norman G.J., et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010, 138:1357-1364.
155. Manco M., Bedogni G., Marcellini M., et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut 2008, 57:1283-1287.
156. Anthropometry procedures manual. National Health and Nutrition Examination Survey. Center for Disease Control; 2000. Available at: Accessed September 12, 2009. http://www.cdc.gov/nchs/data/nhanes/bm.pdf.
157. Rashid M., Roberts E.A. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000, 30:48-53.
158. Burke J.P., Hale D.E., Hazuda H.P., et al. A quantitative scale of acanthosis nigricans. Diabetes Care 1999, 22:1655-1659.
159. Schwimmer J.B., Pardee P.E., Lavine J.E., et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008, 118:277-283.
160. Moreno M., Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis 2008, 12:825-852. ix.
161. Puri M., Flynn J.T. Management of hypertension in children and adolescents with the metabolic syndrome. J Cardiometab Syndr 2006, 1:259-268.
162. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
163. Guzzaloni G., Grugni G., Minocci A., et al. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. Int J Obes Relat Metab Disord 2000, 24:772-776.
164. Manton N.D., Lipsett J., Moore D.J., et al. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000, 173:476-479.
165. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98:2042-2047.
166. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
167. Adams L.A., Feldstein A., Lindor K.D., et al. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004, 39:909-914.
168. Evans H.M., Shaikh M.G., McKiernan P.J., et al. Acute fatty liver disease after suprasellar tumor resection. J Pediatr Gastroenterol Nutr 2004, 39:288-291.
169. Nakajima K., Hashimoto E., Kaneda H., et al. Pediatric nonalcoholic steatohepatitis associated with hypopituitarism. J Gastroenterol 2005, 40:312-315.
170. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007, 11:191-207. x-xi.
171. Cuadrado A., Orive A., Garcia-Suarez C., et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 2005, 15:442-446.
172. Hashizume H., Sato K., Takagi H., et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2007, 19:827-834.
173. Rubinstein E., Lavine J.E., Schwimmer J.B. Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:380-385.
174. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43:682-689.
175. Bullock R.E., Zaitoun A.M., Aithal G.P., et al. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J Hepatol 2004, 41:685-686.
176. Zen Y., Katayanagi K., Tsuneyama K., et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001, 51:127-131.
177. Koebnick C., Getahun D., Reynolds K., et al. Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. J Pediatr Gastroenterol Nutr 2009, 48:597-603.
178. Feldstein A.E., Charatcharoenwitthaya P., Treeprasertsuk S., et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58:1538-1544.
179. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
180. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
181. Demircioglu F., Kocyigit A., Arslan N., et al. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008, 47:68-75.
182. Pacifico L., Cantisani V., Ricci P., et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 2008, 63:423-427.
183. Aygun C., Kocaman O., Sahin T., et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2008, 53:1352-1357.
184. Nadeau K.J., Klingensmith G., Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr 2005, 41:94-98.
185. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
186. Fan J.G., Li F., Cai X.B., et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007, 22:1086-1091.
187. de Piano A., Prado W.L., Caranti D.A., et al. Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2007, 44:446-452.
188. Reinehr T., Schmidt C., Toschke A.M., et al. Lifestyle intervention in obese children with nonalcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 2009, 94:437-442.
189. Tock L., Prado W.L., Caranti D.A., et al. Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy. Eur J Gastroenterol Hepatol 2006, 18:1241-1245.
190. Wang C.L., Liang L., Fu J.F., et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008, 14:1598-1602.
191. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48:993-999.
192. Vos M.B., Weber M.B., Welsh J., et al. Fructose and oxidized low-density lipoprotein in pediatric nonalcoholic fatty liver disease: a pilot study. Arch Pediatr Adolesc Med 2009, 163:674-675.
193. Nobili V., Manco M., Ciampalini P., et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008, 30:1168-1176.
194. Lavine J.E., Schwimmer J.B., Molleston J.P., et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010, 31:62-70.
195. Aithal G.P., Thomas J.A., Kaye P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
196. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
197. Ratziu V., Giral P., Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135:100-110.
198. Chalasani N.P., Sanyal A.J., Kowdley K.V., et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009, 30:88-96.
199. Sanjay A. A randomized controlled trial of pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS). Hepatology 2009, 50(Suppl 4):90A.
200. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136:734-738.
201. Nobili V., Manco M., Devito R., et al. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006, 24:1553-1561.
202. Nobili V., Manco M., Devito R., et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008, 48:119-128.
203. Obinata K., Maruyama T., Hayashi M., et al. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996, 403:607-613.
204. Dufour J.F., Oneta C.M., Gonvers J.J., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537-1543.
205. Ersoz G., Gunsar F., Karasu Z., et al. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005, 16:124-128.
206. ClinicalTrials.gov Pilot Study of Ursodeoxycholic Acid in Non-Alcoholic Steatohepatitis (URSONASH) Identifier: NCT00470171. Available at:, Accessed February 2, 2009. http://clinicaltrials.gov/ct2/show/NCT00470171
207. Sanyal A., Mudaliar S., Henry R. A new therapy for nonalcoholic fatty liver disease and diabetes? INT-747-the first FXR hepatic therapeutic study. Hepatology 2009, 50(Suppl 4):389A.
208. ClinicalTrials.gov Effects of FXR activation on hepatic lipid and glucose metabolism Identifier: NCT00465751. Available at:, Accessed October 31, 2007. http://clinicaltrials.gov/ct2/show/NCT00465751.
209. Merat S., Malekzadeh R., Sohrabi M.R., et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003, 38:414-418.
210. Pamuk G.E., Sonsuz A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2003, 18:1220-1221.
211. Uygun A., Kadayifci A., Baĝci S., et al. L-Carnitine therapy in non-alcoholic steatohepatitis. Turk J Gastroenterol 2000, 11:196-201.
212. Hyogo H., Tazuma S., Arihiro K., et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57:1711-1718.
213. Nelson A., Torres D.M., Morgan A.E., et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009, 43:990-994.
214. Daniels S.R., Greer F.R. Lipid screening and cardiovascular health in childhood. Pediatrics 2008, 122:198-208.
215. O'Gorman C.S., Higgins M.F., O'Neill M.B. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr Cardiol 2009, 30:482-489.
216. de Ferranti S., Ludwig D.S. Storm over statins-the controversy surrounding pharmacologic treatment of children. N Engl J Med 2008, 359:1309-1312.
217. Zelber-Sagi S., Kessler A., Brazowsky E., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639-644.
218. Klein S., Mittendorfer B., Eagon J.C., et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006, 130:1564-1572.
219. Barker K.B., Palekar N.A., Bowers S.P., et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101:368-373.
220. Dixon J.B., Bhathal P.S., O'Brien P.E. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006, 16:1278-1286.
221. Mathurin P., Hollebecque A., Arnalsteen L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009, 137:532-540.
222. Mattar S.G., Velcu L.M., Rabinovitz M., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005, 242:610-617. [discussion: 618-20].
223. Holterman A.X., Browne A., Dillard B.E., et al. Short-term outcome in the first 10 morbidly obese adolescent patients in the FDA-approved trial for laparoscopic adjustable gastric banding. J Pediatr Gastroenterol Nutr 2007, 45:465-473.
224. Nadler E.P., Reddy S., Isenalumhe A., et al. Laparoscopic adjustable gastric banding for morbidly obese adolescents affects android fat loss, resolution of comorbidities, and improved metabolic status. J Am Coll Surg 2009, 209:638-644.
225. Nadler E.P., Youn H.A., Ren C.J., et al. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. J Pediatr Surg 2008, 43:141-146.
226. Pratt J.S., Lenders C.M., Dionne E.A., et al. Best practice updates for pediatric/adolescent weight loss surgery. Obesity (Silver Spring) 2009, 17:901-910.
227. Park H.S., Han J.H., Choi K.M., et al. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005, 82:1046-1051.
228. Imhof A., Kratzer W., Boehm B., et al. Prevalence of non-alcoholic fatty liver and characteristics in overweight adolescents in the general population. Eur J Epidemiol 2007, 22:889-897.
229. Zhou Y.J., Li Y.Y., Nie Y.Q., et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007, 13:6419-6424.
230. Tominaga K., Fujimoto E., Suzuki K., et al. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med 2009, 14:142-149.